Semaglutide and tirzepatide are used to treat type 2 diabetes and manage obesity. Both are part of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class, which work by mimicking the hormone GLP-1 to regulate blood sugar levels and aid in weight loss. 

The key difference lies in their additional actions. While semaglutide exclusively targets GLP-1, tirzepatide also acts on glucose-dependent insulinotropic polypeptide (GIP), offering a dual approach. This unique mechanism of tirzepatide may enhance its effectiveness in weight loss. Clinical studies indicate that the combined effect on GLP-1 and GIP can provide more significant weight loss benefits compared to semaglutide alone. (Source)